In total, 11 patients harbored PI3K pathway lesions including two patients for whom pre-treatment tumor tissue sequencing identified PTEN loss-of-function mutations (Fig. 2a), and nine patients for whom baseline plasma sequencing identified additional PTEN or PIK3CA mutations (Supplemental Fig. 7a). The gene discussed is PIK3CA; the disease is neoplasm.